133 followers
Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial https://t.co/0bn9CeQkLi
Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial https://t.co/0bn9CeQkLi
New Research: Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial: Sodium glucose cotransporter 2 (SGLT2) inhibitors have both glucose-lowering and diuretic effects. We… https://t.co/KhbhYmv1GK #medicalcar